DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 11.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,395 shares of the medical device company’s stock after acquiring an additional 343 shares during the period. Harvest Fund Management Co. Ltd’s holdings in DexCom were worth $415,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC acquired a new stake in DexCom in the fourth quarter worth $325,000. Linden Thomas Advisory Services LLC increased its holdings in shares of DexCom by 2.5% during the fourth quarter. Linden Thomas Advisory Services LLC now owns 13,376 shares of the medical device company’s stock valued at $1,660,000 after purchasing an additional 330 shares during the period. Parkside Financial Bank & Trust increased its holdings in shares of DexCom by 11.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,086 shares of the medical device company’s stock valued at $259,000 after purchasing an additional 218 shares during the period. New York State Common Retirement Fund increased its holdings in shares of DexCom by 35.8% during the fourth quarter. New York State Common Retirement Fund now owns 456,559 shares of the medical device company’s stock valued at $56,654,000 after purchasing an additional 120,236 shares during the period. Finally, Duality Advisers LP acquired a new position in shares of DexCom during the fourth quarter valued at $5,128,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 14,639 shares of DexCom stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the completion of the transaction, the chief operating officer now owns 273,913 shares in the company, valued at approximately $36,816,646.33. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Jereme M. Sylvain sold 3,363 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now owns 71,142 shares in the company, valued at $8,304,405.66. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 14,639 shares of the business’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $134.41, for a total value of $1,967,627.99. Following the sale, the chief operating officer now owns 273,913 shares of the company’s stock, valued at approximately $36,816,646.33. The disclosure for this sale can be found here. Insiders have sold a total of 189,375 shares of company stock valued at $25,530,859 in the last 90 days. 0.41% of the stock is owned by corporate insiders.

DexCom Stock Performance

DXCM traded up $3.87 during midday trading on Wednesday, reaching $137.87. The company’s stock had a trading volume of 3,229,887 shares, compared to its average volume of 2,962,265. The stock has a market cap of $53.15 billion, a P/E ratio of 104.94, a PEG ratio of 2.26 and a beta of 1.20. The company has a fifty day simple moving average of $130.15 and a 200 day simple moving average of $117.74. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. DexCom’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 EPS. Research analysts expect that DexCom, Inc. will post 1.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DXCM. Royal Bank of Canada began coverage on DexCom in a research note on Tuesday, March 12th. They set an “outperform” rating and a $165.00 target price for the company. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Citigroup raised their target price on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Raymond James increased their price target on DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Finally, UBS Group increased their price objective on DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.